Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01561950 · ClinicalTrials.gov registry record · Phase 1
Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 1
- Development phase
- 91
- Enrollment target
NCT01561950 is a Phase 1 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 91 participants.
The verdict
NCT01561950, a Phase 1 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 91 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (Plavix®).
Interventions
- DRUG placebo
- DRUG clopidogrel
- DRUG eptacog alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01561950
The ClinicalTrials.gov registry entry for NCT01561950 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT01561950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01561950 about?
NCT01561950 is a clinical study titled "Efficacy of Activated Recombinant Human Factor VII in Healthy Volunteers Treated for Punch Biopsy Mediated Bleeding". This trial is conducted in the United States of the America (USA). The aim of this trial is to evaluate the effectiveness of activated recombinant human factor VII to mitigate experimentally-induced bleeding in healthy volunteers treated with clopidogrel (Plavix®).
What is the current status of trial NCT01561950?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2008-05. Estimated completion is 2009-01.
What interventions are being tested in trial NCT01561950?
The interventions under investigation include: placebo (DRUG), clopidogrel (DRUG), eptacog alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT01561950?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.